• About us
  • Core Technology
  • Bio-Service
  • Investors
  • Careers
中文 English
  • About us
    • Introduction
    • Information
      • Announcement
      • Events
    • Management Team
      • Members
      • Consultants
    • Contact us
  • Core Technology
    • New medicine development platform
      • Skin diseases
      • metabolic diseases
      • Anti-inflammation
      • Diseases related to deficient mitochondrion
      • Others
  • Bio-Service
    • Scientific products
      • Western Blot
      • Cell Culture Supplement
      • Protein Isolation
      • Protein Quantification
      • Dyes and Buffer
    • Supplier
      • Lumiprobe
      • Rigaku Reagents
    • Service
      • Quantitative MS and systematic biological analysis experiment service
      • Protein identity certification experiment service
      • Microarray and biological information analysis experiment service
  • Investors
  • Careers

About us

Founded in 2012 and granted the qualification of biomedicine company by the Ministry of Economic Affairs in 2015, Energenesis Biomedical Co., Ltd. aspires to become a new star in biotech industry.
MORE

Information

  • 2021-07 Energenesis Biomedical Announces Positive End-of-Phase 2 Meeting with FDA on ENERGI-F703 for the Treatment of Diabetic Foot Ulcers
  • 2021-04 The Japan patent “Compound for Activating AMPK and Used Thereof” is granted.
  • 2021-02 The Korean patent “Compound for Activating AMPK and Used Thereof” is granted.
  • 2020-12 The Canada patent “Compound for Activating AMPK and Used Thereof” is granted.
  • 2020-12 Energenesis Biomedical won the 17th National Innovation Award-Enterprise Innovation Award
MORE

New medicine development platform

ENERGI-F703

ENERGI-F701

  • +886-2-26270835
  • +886-2-26270836
  • 6F.-3, No.21, Ln.583, Ruiguang Rd., Neihu Dist., Taipei 11492, Taiwan (R.O.C.)
Copyright © 2017 ENERGENESIS BIOMEDICAL CO., LTD. All Rights Reserved. Design by choice